The role of carbapenems in initial therapy for serious Gram-negative infections

Table 2 Emergence of imipenem resistance during treatment of Pseudomonas pneumonia

Authors (year) [ref.]	Daily dose (g)	Treatment-emergent resistance (n/total [%])
Salata et al. (1985) [36]	1.5 to 3	6/10 (60)
Quinn et al. (1986) [38]
Norrby et al. (1993) [35]	2	6/19 (32)
Cometta et al. (1994) [32]	2^a	14/21 (67)
Fink et al. (1994) [33]	3	17/32 (53)
Jaccard et al. (1998) [34]	2	6/24 (25)
Zanetti et al. (2003) [37]	2	9/27 (33)

ISSN: 1364-8535